Suppr超能文献

巨噬细胞炎性蛋白-1

Macrophage inflammatory protein-1.

作者信息

Maurer M, von Stebut E

机构信息

Department of Dermatology, University of Mainz, Langenbeckstr. 1, Mainz 55101, Germany.

出版信息

Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6. doi: 10.1016/j.biocel.2003.10.019.

Abstract

Macrophage inflammatory protein (MIP)-1alpha was identified 15 years ago as the first of now four members of the MIP-1 CC chemokine subfamily. These proteins termed CCL3 (MIP-1alpha), CCL4 (MIP-1beta), CCL9/10 (MIP-1delta), and CCL15 (MIP-1gamma) according to the revised nomenclature for chemokines are produced by many cells, particularly macrophages, dendritic cells, and lymphocytes. MIP-1 proteins, which act via G-protein-coupled cell surface receptors (CCR1, 3, 5), e.g. expressed by lymphocytes and monocytes/macrophages (MPhi), are best known for their chemotactic and proinflammatory effects but can also promote homoeostasis. The encouraging results of preclinical studies in murine models of inflammation, i.e. asthma, arthritis, or multiple sclerosis, have led to the development of potent CCR3 and 5 antagonists, some of which are currently being tested in first clinical trials.

摘要

巨噬细胞炎性蛋白(MIP)-1α于15年前被确定为MIP-1 CC趋化因子亚家族目前四个成员中的第一个。根据趋化因子的修订命名法,这些蛋白被称为CCL3(MIP-1α)、CCL4(MIP-1β)、CCL9/10(MIP-1δ)和CCL15(MIP-1γ),由许多细胞产生,特别是巨噬细胞、树突状细胞和淋巴细胞。MIP-1蛋白通过G蛋白偶联细胞表面受体(CCR1、3、5)发挥作用,例如由淋巴细胞和单核细胞/巨噬细胞(MPhi)表达,其趋化和促炎作用最为人所知,但也可促进体内平衡。在炎症小鼠模型(即哮喘、关节炎或多发性硬化症)的临床前研究中取得的令人鼓舞的结果,促使人们开发出了强效的CCR3和5拮抗剂,其中一些目前正在进行首次临床试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验